The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at 30 C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50 C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises a non-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound.

Si(R.sup.1).sub.a(R.sup.2).sub.4-a(1)

##STR00001##

The invention provides mesotrione copper chelate form I and mesotrione copper chelate form II. A process for preparing mesotrione copper chelate form I and mesotrione copper chelate form II is also disclosed. Further, the present invention provides process for preparing mesotrione metal chelate polymorphs and agrochemical formulations comprising such polymorphs.

A novel onium salt having formula (1) and a resist composition comprising the same as a quencher are provided. When the resist composition is processed by photolithography using high-energy radiation, there is formed a resist pattern which is improved in LWR and CDU. In formula (1), R.sup.1, R.sup.2 and R.sup.3 each are a C.sub.1-C.sub.20 monovalent hydrocarbon group which may contain a heteroatom exclusive of fluorine, and Z.sup.+ is a sulfonium, iodonium or ammonium cation.

The present disclosure relates to HIF-2 inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2 scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The present disclosure relates to HIF-2 inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2 scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

A chemoselective and reactive Mn(CF.sub.3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic CH hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

A chemoselective and reactive Mn(CF.sub.3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic CH hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at 30 C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50 C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises a non-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound. ##STR00001##